SCYNEXIS, Inc.

SCYX

US8112922005

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
2.67 ^USD	+1.91%		+35.53%	+19.73%

May. 08	Earnings Flash (SCYX) SCYNEXIS Reports Q1 Revenue $1.4M	MT
May. 08	SCYNEXIS, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

SCYNEXIS, Inc. Appoints Nkechi Azie as Vice President of Clinical Development

June 14, 2019 at 08:30 am EDT

SCYNEXIS, Inc. announced appointment of Nkechi Azie, MD, MBA, FIDSA, as Vice President of Clinical Development, effective June 10, 2019. Dr. Azie will lead clinical development activities and strengthen medical affairs efforts in anticipation of ibrexafungerp's potential approval and commercial launch. Dr. Azie will report to SCYNEXIS' Chief Medical Officer, David Angulo, M.D.

Latest news about SCYNEXIS, Inc.

Earnings Flash (SCYX) SCYNEXIS Reports Q1 Revenue $1.4M	May. 08	MT
SCYNEXIS, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases	Apr. 09	CI
SCYNEXIS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
SCYNEXIS, Inc. Presents Preclinical Data on Second Generation Fungerp SCY-247 Against Mucormycosis At the 11Th Advances Against Aspergillosis and Mucormycosis Conference	Jan. 29	CI
SCYNEXIS Amends License Agreement With GlaxoSmithKline Intellectual Property; Shares Drop Premarket	Jan. 03	MT
Earnings Flash (SCYX) SCYNEXIS Reports Q3 Revenue $1.8M	Nov. 13	MT
SCYNEXIS, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
SCYNEXIS, Inc. Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology	23-10-24	CI
SCYNEXIS Recalls Two Lots of Brexafemme Due to Potential for Cross Contamination with Non-Antibacterial Drug Substance	23-09-28	MT
SCYNEXIS, Inc. Issues A Voluntary Nationwide Recall of BREXAFEMME® (Ibrexafungerp Tablets) Due to Potential for Cross Contamination with A Non-Antibacterial ß-Lactam Drug Substance	23-09-27	CI
Sector Update: Health Care Stocks Advancing Late Afternoon	23-09-25	MT
Top MIdday Decliners	23-09-25	MT
Ladenburg Thalmann Cuts SCYNEXIS Price Target to $7.50 From $15, Maintains Buy Rating	23-09-25	MT
SCYNEXIS Recalls Brexafemme on Cross Contamination Risk; Shares Fall	23-09-25	MT
Earnings Flash (SCYX) SCYNEXIS Posts Q2 Revenue $131.5M	23-08-14	MT
SCYNEXIS, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
SCYNEXIS Says New Drug Application for Vulvovaginal Candidiasis Treatment Accepted for Review in China	23-07-20	MT
SCYNEXIS, Inc.(NasdaqGM:SCYX) dropped from Russell Microcap Value Index	23-06-23	CI
SCYNEXIS, Inc.(NasdaqGM:SCYX) dropped from Russell 3000E Value Index	23-06-23	CI
Scynexis Says $25 Million Performance-Based Development Milestone Achieved as Part of GSK License Deal	23-06-21	MT
Scynexis Closes Exclusive Brexafemme License Deal With GSK	23-05-12	MT
SCYNEXIS, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Guggenheim Adjusts Price Target on SCYNEXIS to $9 From $8, Maintains Buy Rating	23-04-03	MT
Earnings Flash (SCYX) SCYNEXIS Posts Q4 Revenue $1.4M	23-03-31	MT

Chart SCYNEXIS, Inc.

Duration

Period

More charts

Company Profile

SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.

Sector

Pharmaceuticals

Calendar

2024-06-19 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for SCYNEXIS, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.67 USD

Average target price

6.875 USD

Spread / Average Target

+157.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SCYNEXIS, INC.	+19.73%	98.98M
ELI LILLY AND COMPANY	+37.78%	705B
NOVO NORDISK A/S	+32.82%	583B
JOHNSON & JOHNSON	-3.51%	364B
MERCK & CO., INC.	+19.94%	332B
ABBVIE INC.	+5.14%	291B
ASTRAZENECA PLC	+16.64%	238B
ROCHE HOLDING AG	-4.13%	210B
NOVARTIS AG	+10.63%	209B
AMGEN INC.	+9.32%	169B

Other Pharmaceuticals

SCYNEXIS, Inc.

Equities

SCYX

US8112922005

Pharmaceuticals

SCYNEXIS, Inc. Appoints Nkechi Azie as Vice President of Clinical Development

EPS Revisions